"Designing Growth Strategies is in our DNA"

Dry Eye Syndrome Market Size, Share & COVID-19 Impact Analysis, By Product (Anti-inflammatory Products {Cyclosporin, Corticosteroids, and Others}, Artificial Tears and Lubricants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2023-2030

Region : Global | Format: PDF | Report ID: FBI102413

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The dry eye syndrome market size was valued at USD 6.61 billion in 2022 and is projected to grow from USD 7.02 billion in 2023 to USD 11.26 billion by 2030, exhibiting a CAGR of 7.0% during 2023-2030. North America dominated the global market with a share of 46.89% in 2021.


Dry Eye Syndrome (DES) or Dry Eye Disease (DES), which is also called Keratoconjunctivitis Sicca (KCS), is a common ophthalmic condition that occurs when the person doesn’t have enough quality tears to lubricate or nourish the eye. The symptoms include redness, stinging, scratching, or burning sensation, light sensitivity, watery eyes, and stringy mucus near the eye and blurry vision. As per an article published by the BMC Ophthalmology in February 2022, signs of eye dryness were reported in 5–30% of the elderly subjects, and the frequency of dry eye was 8.4% for those less than 60 years, 15% among 70-79 years, and 20% for patients over 80 years.


Moreover, with increasing age, the ability of the lacrimal glands to produce tears decreases leading to this condition. The condition has also been more prevalent amongst post-menopausal women. A study was published by the National Library of Medicine in June 2021, in a group of 1947 perimenopausal and postmenopausal women, aged between 45 and 79 years, where the overall prevalence of DED symptoms was 79%, and was increasing significantly in postmenopausal women. These trends will lead to an increase in demand for therapeutic measures and contribute to the growth of the global market during the forecast period.


COVID-19 IMPACT 


Decline of Non-Essential Treatment During COVID-19 Negatively Impacted the Market Growth


During the COVID-19 outbreak, a number of studies found that COVID-19 patients were having persistent dry eye symptoms for weeks and months after the recovery. This led to an increase in the prevalence of this condition as this is a common ophthalmic disease. Also, during the COVID-19, people’s work and study mode gradually shifted from offline to online, which resulted in an increase in prevalence of this condition. On the other hand, consultations for all the non-essential therapeutic measures were observed to have witnessed a decline during the pandemic, which resulted in a decrease in demand for these therapeutics.



  • As per a study published by the Wiley Public Health Emergency Collection in March 2022, 64 patients were evaluated for 82 days after the onset of COVID-19 symptoms, out of which 11% reported signs and symptoms of dry eye disease. However, key drugs, such as AbbVie’s Restasis, witnessed a steep decline in their revenues for FY 2020.


However, market players witnessed a steady growth in their revenues, owing to the development of new sales channels in private hospitals and retail stores.



  • In 2021 Novartis witnessed a major growth in the annual revenue of Xiidra, which was USD 192.0 million, USD 376.0 million, and USD 468.0 million in the financial year 2019, 2020, and 2021, respectively. The growth in revenue of Xiidra was mainly driven by sustainable increased brand awareness among diagnosed patients suffering from signs and symptoms of this condition.   


This growth continued in 2022 for some of the prominent players such as Santen Pharmaceuticals Co., which registered a growth of 21.0% for its Diquas ophthalmic solution. Such trends indicate that the market is set for steady growth during the study period.


LATEST TRENDS


Request a Free sample to learn more about this report.


Increasing Incidence of Mask-Associated Dry Eye to Offer Growth Potential


A key trend witnessed in the global market is the increasing incidence of Mask-Associated Dry Eye (MADE). Face masks and face shields were crucial in the fight against COVID-19, and most of the ophthalmologists observed that more and more patients had dry eyes due to the prolonged use of face masks and increase in screen time during the COVID-19 pandemic period.



  • For instance, as per an article published by the Indian Journal of Ophthalmology in February 2021, scientists from the Centre for Ocular Research & Education (CORE), Waterloo, Canada termed dry eye after use of face mask as mask-associated dry eye.


Moreover, after the outbreak of COVID-19, several medical associations reported a spike in cases of dry eye due to continuous use of face masks among people. Also, as the incidence of other infectious diseases, especially air borne diseases grows, the adoption of masks is expected to continue in the forecast period. This prevailing trend will drive the adoption rate of these products leading to market growth during the forecast period.


DRY EYE SYNDROME MARKET GROWTH FACTORS


Growing Prevalence of Dry Eye Syndrome to Drive the Market Growth


One of the critical drivers that positively impacts the global market is the extensive increase in the global prevalence of this condition. The prevalence of this chronic condition varies with age. However, the prevalence is increasing in the young as well as the older population due to growing usage of screens, improper diet, growing use of contact lenses, and rise in the number of LASIK surgeries. 



  • As per an epidemiological study published by UpToDate, Inc., in January 2023, globally the prevalence of Dry Eye Disease (DED) ranged from 5%-50%. Therefore, the overall burden of dry eye syndrome is one of the highest in terms of cost and healthcare services as it affects a considerable proportion of the population.


Increase in the prevalence will propel the demand for more effective therapeutic measures for this disease, which will drive the dry eye syndrome market growth during the forecast period.


Strong R&D Investments to Support Pipeline Candidates will Boost the Market Growth


The increasing prevalence of dry eye syndrome is propelling the demand for efficient therapeutic options leading to better patient outcomes. The market growth will grow as the adoption rate and accessibility of these products will increase across the globe. A number of market players are upscaling their research activities and focusing on getting regulatory approval of therapeutically effective novel products, which will boost the growth of the global market in the forecast period.



  • For instance, in September 2022, TearSolutions reported positive results for its pipeline candidate Lacripep from its first-in-human study, which is indicated to treat dry eye disease. Such positive results of pipeline candidates will accelerate the development and introduction process of novel drugs, eventually leading to the market growth.


RESTRAINING FACTORS


Low Importance Given to Ocular Health May Limit the Market Growth Prospects


One of the critical factors limiting the market growth is the attitude of the general population toward ocular health. People do not visit ophthalmologists on a regular basis unless there is a major symptomatic condition. Dry eye symptoms, such as redness, burning, and so on, are many times ignored and are not diagnosed. This results in the reduction of the patient pool that can be treated with these prescription drugs. Hence, this leads to a lower adoption rate of these eye care products, which limits the market expansion potential.



  • According to a survey conducted in the U.K. and published by the Broadgreen University Hospital NHS Trust in March 2022, it was revealed that approximately 5 million people have never had an eye test and a quarter of the people surveyed haven’t had an eye test in more than three years.


Lower importance given to ocular conditions such as dry eye syndrome by the prospective patient population will limit the expansion of this market as it may hinder the adoption rate of these therapeutics in the forecast period.


SEGMENTATION


By Product Analysis


To know how our report can help streamline your business, Speak to Analyst


Artificial Tears and Lubricants Segment Dominates the Market Due to High Adoption Rate in 2022


Based on product, the market is segmented into anti-inflammatory products, artificial tears and lubricants, and others.


The artificial tears and lubricants segment dominated the global dry eye syndrome market share in 2022. The segment’s growth is mainly driven by continuous launches of Over-The-Counter (OTC) medications to meet the rising demand from patients suffering from this condition. In April 2022, Théa Pharma Inc. launched the iVIZIA line of OTC eye-care products in the U.S., which helps in terms of lubrication for the dry eye syndrome. Such launches made by market players will lead to the increase in adoption of these products to meet the demand, and that will lead to the market growth during the forecast period.


The anti-inflammatory products segment held the second largest market share in 2022. These products have shown better treatment outcomes, which is driving its demand amongst the patient population and is anticipated to fuel the growth of this segment. In October 2021, Sun Pharmaceutical Industries Ltd. received an approval for Ikervis in Australia. It is a cyclosporin indicated to treat the inflammation caused by dry eye. Such regulatory approvals are expected to drive the segment’s growth during the forecast period.


The others segment includes the varenicline solution (Tyrvaya) nasal spray and other pipeline candidates for dry eye syndrome, which will display stable growth over the foracast period, after their prospective launches.


By Distribution Channel Analysis


Higher Obtaining of Therapeutics through Hospital Pharmacies Propelled the Dominance in 2022


By distribution channel, the market is classified into hospital pharmacies, retail pharmacies, online pharmacies, and others.


Hospital pharmacies segment held the majority share in 2022. The domination of the segment is attributed as increasing number of the medicines for the treatment of this disease. These medications can only be used after doing detailed inspections by qualified medical experts at these organizations.


Retail pharmacies fragment held the largest share after the hospital pharmacies segment in 2022, due to the use of the settings for attaining of prescription refills. The online pharmacies segment is set to grow at the maximum CAGR during the forecast period. The segment’s growth due to increasing rate of adoption of digital pharmaceutical platforms making medication procurement process easy by delivery.


The others segment held a comparatively lower share and is expected to grow at lower CAGR during the forecast period. Hence, all these factors collectively will fuel the global market growth.


REGIONAL INSIGHTS


North America Dry Eye Syndrome Market Size, 2022 (USD billion)

To get more information on the regional analysis of this market, Request a Free sample


In terms of region, the global market is studied into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.


The North America dry eye syndrome treatment market size was valued at USD 3.10 billion in 2022 and is likely to dominate the market throughout the forecast period due to increasing prevalence of this disease and growing adoption of drugs for the treatment. For instance, in March 2022, based on a report published by Eyes On Eyecare, dry eye disease is more prevalent than ever, with an estimated 35.0 million people in the U.S. suffering from this disease. Such rising prevalence is likely to surge the demand of these therapeutic measures, contributing to the regional growth during the forecast period.


The Europe market is expected to grow with substantial CAGR during forecast period, including the increase in the number of geriatric individuals suffering from this condition, which is likely to propel market growth across the region. For instance, in 2022, around 22.4% of the population in Germany fell under the age group of 65 years and above, which is anticipated to increase the burden of the disease in Germany during the forecast period. This will offer a lucrative opportunity for the market players to launch novel products during the forecast period.


The Asia Pacific market is expected to grow with highest CAGR during the forecast period and the growth in this region is primarily attributed to the higher preference of the patients toward the OTC drugs, new drug launches, and the rising prevalence of this condition across the region. Latin America and the Middle East and Africa are estimated to grow at a comparatively lower CAGR during the forecast period. This is due to comparatively lack of awareness amongst people in these regions coupled with low out-of-pocket expenditure for the diagnosis and treatment of this disease.


KEY INDUSTRY PLAYERS


AbbVie, Inc. Held a Significant Market Share in 2022 Due to Strong Brand Presence


In terms of competitive landscape, AbbVie, Inc. is one of the leading market players, owing to its robust distribution network and strong brand presence especially in the OTC artificial tear and lubricants segment with its leading brand of the Refresh range of artificial tears and lubricants. Alcon also held a considerable market share in 2022 and is focusing on maintaining its position by making strategic alliances to expand its portfolio.


Some other key players of the market include Novartis AG and Santen Pharmaceutical Co., Ltd, which are focusing on new product launches, getting regulatory approval in emerging countries to strengthen its business operations and supply chain network. Furthermore, there are several market players that are focusing on expanding research and development of novel drugs for the treatment of this condition. Some of them include Sun Pharmaceuticals Industries, Inc., Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Vision Care, Inc., and Sentiss Pharma Pvt. Ltd.


LIST OF KEY COMPANIES PROFILED IN DRY EYE SYNDROME MARKET:



KEY INDUSTRY DEVELOPMENTS:



  • August 2022: Novaliq GmbH submitted New Drug Application (NDA) to the U.S. FDA for the approval for CyclASol (cyclosporine ophthalmic solution), which is a topical anti-inflammatory and immunomodulating ophthalmic drug solution, developed for the treatment of dry eye disease.

  • December 2021: Ntc s.r.l. entered into a strategic partnership with I-MED Pharma Inc. to launch I-DEFENSE, HA-based dry eye ointment to the U.S. market.

  • September 2021: Bausch Health Companies Inc. collaborated with Novaliq GmbH to develop the investigational drug NOV03 (perfluorohexyloctane), an eye drop used to treat the signs and symptoms of Dry Eye Disease (DED). The pipeline candidate is under phase 3 clinical study.

  • April 2021: Alcon launched Systane Hydration Multi-dose preservative free lubricant eye drops in the U.S. market to provide long-lasting relief to patients with dry eyes.

  • February 2021: AbbVie Inc. launched a new lubricant eye drop named REFRESH DIGITAL that supports all three layers of the tear film to keep eyes hydrated.


REPORT COVERAGE


An Infographic Representation of Dry Eye Syndrome Market

To get information on various segments, share your queries with us



The global market research report provides qualitative and quantitative insights on the global market and a detailed analysis of global market size & growth rate for all possible segments in the market. Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights presented in the report are the prevalence of dry eye disease, by key countries, key industry developments, pipeline analysis, new product launches, regulatory scenario, reimbursement policies, overview of novel approaches to treat dry eye, key industry trends, healthcare industry overview, the impact of COVID-19 on the market, and overview of over the counter eye lubricants in the market.


Report Scope & Segmentation 






















































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 7.0% from 2023 to 2030



Unit



Value (USD billion)



Segmentation



By Product, Distribution Channel, and Region



By Product




  • Anti-inflammatory Products

    • Cyclosporine

    • Corticosteroids

    • Others



  • Artificial Tears and Lubricants

  • Others



By Distribution Channel




  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Others



By Region




  • North America (By Product, By Distribution Channel, By Country)

    • U.S.

    • Canada



  • Europe (By Product, By Distribution Channel, By Country/Sub-Region)

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Scandinavia

    • Rest of Europe



  • Asia Pacific (By Product, By Distribution Channel, By Country/Sub-Region)

    • Japan

    • China

    • India

    • Australia

    • Southeast Asia

    • Rest of Asia Pacific



  • Latin America (By Product, By Distribution Channel, By Country/Sub-Region)

    • Brazil

    • Mexico

    • Rest of Latin America



  • Middle East & Africa (By Product, By Distribution Channel, By Country/Sub-Region)

    • GCC

    • South Africa

    • Rest of Middle East & Africa








Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 6.61 billion in 2022 and is projected to reach USD 11.26 billion by 2030.

In 2022, the North America market stood at USD 3.10 billion.

The market will grow at a CAGR of 7.0% in the forecast period (2023-2030).

Artificial tears and lubricants segment is expected to be the leading segment in this market during the forecast period.

Rising R&D initiatives of market players to support and accelerate the development of pipeline candidates to meet the growing needs of the patients suffering from this condition are some of the major factors driving the global market.

AbbVie Inc., Alcon, and Novartis AG are the leading market players in the global market.

North America region dominated the market in 2022.

The growing awareness about this condition especially among aging population and innovative product launches are expected to drive the adoption of these products.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • May, 2023
  • 2022
  • 2019-2021
  • 120

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X